Protagonist Therapeutics appoints Asif Ali as EVP, CFO effective April 18, 2022

Protagonist Therapeutics, Inc

Asif Ali, 48, appointed EVP, CFO; previously VP Finance & CAO at Theravance Biopharma (2018-2022) and VP Corp Controller at Depomed.
Annual base salary $425,000; eligible for discretionary bonus up to 40% of base salary.
Initial equity grant: option to purchase 82,500 shares (4-yr vest, 1-yr cliff) and 13,750 RSUs (4-yr equal installments).
No family relationships with any executive officer or director; no material interests in reportable transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Asif Ali

Executive Vice President, Chief Financial Officer

PTGX · Protagonist Therapeutics, Inc

Effective: 2022-04-18
Filed: March 31, 2022, 7:59 PM ET

On March 25, 2022, the Board of Directors of Protagonist Therapeutics, Inc. (the “Company”) approved the appointment of Asif Ali, 48, to the position of Executive Vice President, Chief Financial Officer, effective on commencement of Mr. Ali’s employment with the Company (April 18, 2022).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Asif Ali was appointed as Executive Vice President, Chief Financial Officer at Protagonist Therapeutics, Inc.

Action: appointed
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On March 25, 2022, the Board of Directors of Protagonist Therapeutics, Inc. (the “Company”) approved the appointment of Asif Ali, 48, to the position of Executive Vice President, Chief Financial Officer, effective on commencement of Mr. Ali’s employment with the Company (April 18, 2022).

View on SEC.gov

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-22-041035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.